Abstract:Systemic lupus erythematosus (SLE) is an autoimmune and multisystem disease with a high public health impact. Lupus nephritis (LN), commonly known as renal involvement in SLE, is associated with a poorer prognosis and increased rates of morbidity and mortality in patients with SLE. Identifying new urinary biomarkers that can be used for LN prognosis or diagnosis is essential and is part of current active research. In this study, we applied an untargeted metabolomics approach involving liquid and gas chromatography coupled with mass spectrometry to urine samples collected from 17 individuals with SLE and no kidney damage, 23 individuals with LN, and 10 clinically healthy controls (HCs) to identify differential metabolic profiles for SLE and LN. The data analysis revealed a differentially abundant metabolite expression profile for each study group, and those metabolites may act as potential differential biomarkers of SLE and LN. The differential metabolic pathways found between the LN and SLE patients with no kidney involvement included primary bile acid biosynthesis, branched-chain amino acid synthesis and degradation, pantothenate and coenzyme A biosynthesis, lysine degradation, and tryptophan metabolism. Receiver operating characteristic curve analysis revealed that monopalmitin, glycolic acid, and glutamic acid allowed for the differentiation of individuals with SLE and no kidney involvement and individuals with LN considering high confidence levels. While the results offer promise, it is important to recognize the significant influence of medications and other external factors on metabolomics studies. This impact has the potential to obscure differences in metabolic profiles, presenting a considerable challenge in the identification of disease biomarkers. Therefore, experimental validation should be conducted with a larger sample size to explore the diagnostic potential of the metabolites found as well as to examine how treatment and disease activity influence the identified chemical compounds. This will be crucial for refining the accuracy and effectiveness of using urine metabolomics for diagnosing and monitoring lupus and lupus nephritis.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the early diagnosis of systemic lupus erythematosus (SLE) and its renal complication - lupus nephritis (LN). Specifically, the research aims to identify potential biomarkers that can be used to distinguish SLE patients without renal damage from LN patients through urinary metabolomics analysis. This helps to improve the diagnostic methods of SLE and LN, especially providing a non - invasive diagnostic means to replace the current gold standard - renal biopsy, so as to monitor disease progression and treatment response more effectively. Research background: - **SLE** is a chronic autoimmune disease that affects multiple organs, among which **lupus nephritis (LN)** is one of the most important complications and seriously affects the prognosis of patients. - Currently, the diagnosis of LN depends on invasive renal biopsy, which is not suitable for frequent monitoring and cannot predict patients' response to treatment. - Therefore, the search for new non - invasive biomarkers is crucial for the early diagnosis and monitoring of SLE and LN. Research methods: - The research adopted a non - targeted metabolomics method, combined with liquid chromatography - mass spectrometry (LC - QTOF - MS) and gas chromatography - mass spectrometry (GC - QTOF - MS), to analyze urine samples from 17 SLE patients without renal damage, 23 LN patients and 10 healthy controls. - Through statistical analysis of metabolites, the differential metabolites among each group were identified and their diagnostic value as potential biomarkers was evaluated. Main findings: - The study found that there were significant differences in metabolite expression among different groups, and these differences may reflect different pathophysiological processes of SLE and LN. - In particular, in LN patients, the concentrations of certain metabolites (such as glyceryl monopalmitate, glutamate and glycolic acid) were significantly increased or decreased, and these metabolites have high diagnostic potential. - Through receiver operating characteristic curve (ROC) analysis, glyceryl monopalmitate, methylglutamate and glycolic acid were determined as high - potential biomarkers for distinguishing SLE patients without renal damage from LN patients. Conclusion: - This study shows the application potential of metabolomics in the early diagnosis of SLE and LN, especially in the discovery of non - invasive biomarkers. - However, the study also points out that the influence of drugs and other external factors on metabolomics results cannot be ignored, and future verification in a larger sample size is required to further confirm the diagnostic value of these biomarkers. In general, through the metabolomics method, this paper has successfully identified some potential urinary biomarkers, which are expected to be used for the early diagnosis and monitoring of SLE and LN, thereby improving patient management and prognosis.

Urinary metabolomic profiling of a cohort of Colombian patients with systemic lupus erythematosus

THU0247 LRRN4: A NOVEL PROGNOSTIC BIOMARKER OF RENAL OUTCOME IN LUPUS NEPHRITIS PATIENTS

Urinary metabolomic study of systemic lupus erythematosus based on gas chromatography/mass spectrometry.

Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis

Nontargeted serum metabolomics analysis and potential biomarkers for systemic lupus erythematosus

Serum Metabolomic Profiling in Patients with Systemic Lupus Erythematosus by GC/MS.

Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis

Urinary Biomarkers for Lupus Nephritis: A Systems Biology Approach

Urinary microbiome profiling as a non-invasive tool for identifying biomarkers in systemic lupus erythematosus and lupus nephritis

Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis

Clinical and Immunological Factors Associated with the Progression of Lupus Nephritis in a Population from the Colombian Caribbean

Integrative analysis of systemic lupus erythematosus biomarkers: Role of fecal hsa-mir-223–3p and gut microbiota in transkingdom dynamics

Serum Proteome and Metabolome Uncover Novel Biomarkers for the Assessment of Disease Activity and Diagnosing of Systemic Lupus Erythematosus

Lipidomic And Metabolomic Profiling Reveals Novel Candidate Biomarkers In Active Systemic Lupus Erythematosus

Urine Extracellular Vesicles Size Subsets as Lupus Nephritis Biomarkers

A review on the novel biomarkers of systemic lupus erythematosus discovered via metabolomic profiling

Biomarkers in Systemic Lupus Erythematosus along with Metabolic Syndrome

Serum Metabolic Fingerprints Characterize Systemic Lupus Erythematosus

Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts

Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities